Delisting risk
bioAffinity Technologies
Runs a pathology laboratory and sells a sputum-based lung-cancer assessment test.
$4.90
After-hours close+0.03 (+0.62%)
At close$4.87(−3.75%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 3.85%16.1K sharesInsiders 0.01%56 sharesOther 96.14%402.7K shares
Shares outstanding 418.9K · Float 294.8K · 70.4% free float
Institutions13F, as of Mar 31, 2026
14 holders · 16.1K shares · 8 new positions · 9 increased · 2 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 3.7K | 0.88% | +3.7Knew | May 15, 2026 |
| Geode Capital Management, LLC | 3.2K | 0.77% | +1.2K | May 15, 2026 |
| J. Safra Sarasin Holding AG | 2.8K | 0.68% | +2.8Knew | May 4, 2026 |
| Vanguard Fiduciary Trust Co | 2.1K | 0.49% | +2.1Knew | May 8, 2026 |
| Schonfeld Strategic Advisors LLC | 1.6K | 0.39% | +1.6Knew | May 15, 2026 |
| State Street Corp | 959 | 0.23% | +959new | May 15, 2026 |
| Northern Trust Corp | 848 | 0.20% | 0 | May 14, 2026 |
| UBS Group AG | 614 | 0.15% | +614 | May 5, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Richard K. Crumly | 11.20% | 13G | May 14, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Roberto Rios | director | 56 | 0.01% | Sep 25, 2025 |
1 ten-percent owner holds 440 shares by Form 4, outside the officers-and-directors figure above · 14 people have not refiled in the last 18 months (5.5K shares), so they are not in the figure above
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.